FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Amgen Neupogen Recall

Neupogen (filgrastim) For Injection, 480 mcg/1

Amgen, Inc. · Thousand Oaks, CA

Risk level
Class II
Reported by FDA
Mar 26, 2025
Recall ID
D-0286-2025
Check your lot numberHow we source this data

Summary

Amgen recalled Neupogen starting Feb 27, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0286-2025 on Mar 26, 2025. Reason: Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months. Status: Ongoing.

Why it was recalled

Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.

Product description

Neupogen (filgrastim) For Injection, 480 mcg/1.6 mL (300 mcg/1 mL), 1.6 mL single Dose Vial, Rx Only, For Subcutaneous or Intravenous Use Only, Sterile Solution - No Preservative, Amgen Inc. Thousand Oaks, CA 91320, NDC 55513-546-01 (vial), NDC 55513-546-10 (box).

Lot numbers, UPCs & expiration codes

Lot 1147308, 1154183, Exp.: 2/28/2025; 1156807, 1160222, Exp.: 6/30/2025; 1160223, 1163912, 1167352, Exp.: 2/28/2026; 1171365, 1175057, 1176250, Exp.: 11/30/2026.

Where it was sold

Nationwide in the U.S.A. and Belgium/Luxembourg, Brazil, Chile, Colombia, France/French Guiana, Germany, Ireland, Italy/San Marino, Netherlands, Poland, Spain/Andorra, Sweden, Finland, Switzerland/Liechtenstein, United Kingdom of Great Britain and Northern Ireland, Ireland, Denmark, Canada, Hong Kong, Philippines, Israel, Malaysia, Saudi Arabia, Gibraltar.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0286-2025
Classification
Class II
Status
Ongoing
Recall initiated
Feb 27, 2025
FDA report date
Mar 26, 2025
Quantity
258,750 Vials
Recall type
Voluntary: Firm initiated
Recalling firm
Amgen, Inc.

Original FDA data

Every field from FDA enforcement report D-0286-2025, exactly as published.

Show all FDA fields
City
Thousand Oaks
State
CA
Status
Ongoing
Country
United States
Event ID
96325
Address
1 Amgen Center Dr
Code information
Lot 1147308, 1154183, Exp.: 2/28/2025; 1156807, 1160222, Exp.: 6/30/2025; 1160223, 1163912, 1167352, Exp.: 2/28/2026; 1171365, 1175057, 1176250, Exp.: 11/30/2026.
Postal code
91320-1730
Report date
Mar 26, 2025
Product type
Drugs
Recall number
D-0286-2025
Classification
Class II
Recalling firm
Amgen, Inc.
Product quantity
258,750 Vials
Reason for recall
Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Neupogen (filgrastim) For Injection, 480 mcg/1.6 mL (300 mcg/1 mL), 1.6 mL single Dose Vial, Rx Only, For Subcutaneous or Intravenous Use Only, Sterile Solution - No Preservative, Amgen Inc. Thousand Oaks, CA 91320, NDC 55513-546-01 (vial), NDC 55513-546-10 (box).
Distribution pattern
Nationwide in the U.S.A. and Belgium/Luxembourg, Brazil, Chile, Colombia, France/French Guiana, Germany, Ireland, Italy/San Marino, Netherlands, Poland, Spain/Andorra, Sweden, Finland, Switzerland/Liechtenstein, United Kingdom of Great Britain and Northern Ireland, Ireland, Denmark, Canada, Hong Kong, Philippines, Israel, Malaysia, Saudi Arabia, Gibraltar.
Recall initiation date
Feb 27, 2025
Initial firm notification
Letter
Center classification date
Mar 18, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0286-2025, published Mar 26, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls